Compare ODC & PACB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ODC | PACB |
|---|---|---|
| Founded | 1941 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Miscellaneous manufacturing industries | Biotechnology: Laboratory Analytical Instruments |
| Sector | Consumer Discretionary | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 790.1M | 715.5M |
| IPO Year | N/A | 2010 |
| Metric | ODC | PACB |
|---|---|---|
| Price | $51.08 | $2.14 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $2.00 |
| AVG Volume (30 Days) | 72.9K | ★ 8.7M |
| Earning Date | 12-08-2025 | 11-05-2025 |
| Dividend Yield | ★ 1.41% | N/A |
| EPS Growth | ★ 17.33 | N/A |
| EPS | ★ 3.63 | N/A |
| Revenue | ★ $478,113,000.00 | $154,584,000.00 |
| Revenue This Year | N/A | $4.41 |
| Revenue Next Year | N/A | $11.76 |
| P/E Ratio | $13.77 | ★ N/A |
| Revenue Growth | ★ 5.29 | N/A |
| 52 Week Low | $40.66 | $0.85 |
| 52 Week High | $69.76 | $2.73 |
| Indicator | ODC | PACB |
|---|---|---|
| Relative Strength Index (RSI) | 41.15 | 49.91 |
| Support Level | $45.61 | $2.30 |
| Resistance Level | $55.88 | $2.47 |
| Average True Range (ATR) | 2.29 | 0.20 |
| MACD | -0.38 | -0.03 |
| Stochastic Oscillator | 48.25 | 5.69 |
Oil-Dri Corp of America develops, manufactures, and markets sorbent products made predominantly from clay. Its absorbent offerings, which draw liquid up, include cat litter, floor products, toxin control substances for livestock, and agricultural chemical carriers. The company has two segments based on the different characteristics of two primary customer groups, namely the Retail and Wholesale Products Group, which derives maximum revenue, and the Business-to-Business Products Group. The company's products are sold under various brands such as Cat's Pride, Jonny Cat, Amlan, Agsorb, Verge, Pure-Flo, and Ultra-Clear.
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.